Kiltearn Partners LLP purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 72,600 shares of the biopharmaceutical company's stock, valued at approximately $6,087,000.
A number of other institutional investors also recently made changes to their positions in GILD. Manning & Napier Advisors LLC acquired a new stake in Gilead Sciences in the 2nd quarter worth about $25,328,000. Legal & General Group Plc grew its holdings in Gilead Sciences by 0.8% in the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company's stock valued at $851,743,000 after purchasing an additional 93,068 shares during the period. IRON Financial LLC purchased a new position in Gilead Sciences during the third quarter worth approximately $830,000. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Gilead Sciences by 13.1% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company's stock valued at $19,630,000 after purchasing an additional 33,162 shares during the last quarter. Finally, Cetera Investment Advisers grew its stake in shares of Gilead Sciences by 127.6% during the 1st quarter. Cetera Investment Advisers now owns 213,901 shares of the biopharmaceutical company's stock valued at $15,668,000 after buying an additional 119,909 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.
Gilead Sciences Price Performance
Shares of NASDAQ GILD traded up $1.34 during midday trading on Wednesday, reaching $92.69. The company's stock had a trading volume of 2,221,657 shares, compared to its average volume of 7,063,967. The company has a market cap of $115.52 billion, a price-to-earnings ratio of 1,015.00, a price-to-earnings-growth ratio of 2.81 and a beta of 0.17. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $98.90. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The company has a 50 day moving average price of $87.74 and a 200 day moving average price of $77.31.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same period in the previous year, the firm earned $2.29 earnings per share. Gilead Sciences's revenue for the quarter was up 7.0% compared to the same quarter last year. On average, equities research analysts expect that Gilead Sciences, Inc. will post 4.37 EPS for the current year.
Gilead Sciences Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be issued a dividend of $0.77 per share. The ex-dividend date is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.32%. Gilead Sciences's dividend payout ratio is currently 3,422.22%.
Insider Activity at Gilead Sciences
In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the sale, the insider now directly owns 100,189 shares in the company, valued at $8,398,843.87. The trade was a 1.96 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Johanna Mercier sold 29,357 shares of the stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the transaction, the insider now owns 78,127 shares in the company, valued at approximately $6,545,480.06. This trade represents a 27.31 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 56,947 shares of company stock worth $4,968,674. 0.29% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
A number of research analysts recently weighed in on the company. Piper Sandler lifted their target price on Gilead Sciences from $95.00 to $105.00 and gave the company an "overweight" rating in a report on Thursday, November 7th. Daiwa America raised shares of Gilead Sciences to a "hold" rating in a research report on Monday, November 18th. Wells Fargo & Company lifted their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an "overweight" rating in a research report on Thursday, November 7th. Evercore ISI raised shares of Gilead Sciences to a "strong-buy" rating in a research report on Friday, August 9th. Finally, Robert W. Baird lifted their target price on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a "neutral" rating in a report on Thursday, November 7th. Twelve investment analysts have rated the stock with a hold rating, eleven have given a buy rating and four have given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $95.41.
Read Our Latest Research Report on GILD
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read More
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
